BioSpace News Archive

Daxor Corporation announces the expansion of blood volume analysis through new analyzer purchases and the utilization of Daxor’s ezBVA Lab service.

Vaccinex, Inc. announced it has priced a $3.7 million private placement transaction with a lead investment from a major new investor alongside significant participation from existing investors, including entities affiliated with the Chairman of the Company’s Board of Directors and the Company’s Chief Executive Officer.

Clearside Biomedical, Inc. announced that it has entered into a securities purchase agreement with institutional investors and an existing stockholder, providing for the purchase and sale of 11,111,111 shares of common stock and accompanying warrant to purchase up to 11,111,111 shares of common stock in a registered direct offering.

Fauna Bio announced today a preprint in BioRxiv that senior scientist Ryan J. Sprenger contributed during his PhD. and postdoctoral work which highlights the intricate mechanisms governing skeletal muscle metabolism during animal hibernation.

Cencora, a global healthcare company, released its 2023 Environmental, Social and Governance Report.

Phoreus Biotech is proud to announce the appointment of David Schaefer as its new Chief Executive Officer.

Genprex, Inc. announced the expansion of its nonclinical programs into new indications through Sponsored Research Agreements and Material Transfer Agreements with multiple academic research collaborators to study TUSC2, the tumor suppressor gene used in Genprex’s lead drug candidate, REQORSA, and NPRL2, another tumor suppressor gene.

Cantargia (STO:CANTA) Cantargia AB will publish the company’s year-end report for 2023 on Thursday, February 22, 2024, at 07:00 a.m. CET.

Age-related macular degeneration (AMD) is one of the leading causes of vision loss for people over the age of 55 and today, affecting approximately 2.5 million Canadians.

Trinity Biotech Plc. has applied for a Proprietary Laboratory Analyses (PLA) code for its Early Sjögrens Syndrome Test Panel, to allow for an optimised market access strategy to deliver broader patient access and improved profitability.